Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Investigating the combination of tolinapant & decitabine in a pre-clinical model for T-cell lymphoma

Enrica Marchi • 11 Jun 2022
EHA 2022
Lymphoma Rare Diseases T-Cell Lymphoma Decitabine Tolinapant

Enrica Marchi, MD, PhD, University of Virginia, Charlottesville, VA, discusses a pre-clinical model which investigated the combination of tolinapant and decitabine in T-cell lymphoma. Dr Marchi highlights the early results from this model and explains the synergistic action of tolinapant and decitabine and its potential application in the treatment of T-cell lymphoma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding: Astex Pharmaceuticals, Merck, Celgene/BMS, NomoCan, Kymera Therapeutics
Scientific advisory: Myeloid Therapeutics, Kyowo Kirin, Daiichi Sankyo

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals